Manufacturer
Brand Dragon Pharma
Last Lab Tested None
Core Information
Substance Cagrilintide
Classification Amylin receptor agonist (long-acting)
Active Half-Life 5–7 days
Typical Dosage (Men) 0.3 mg/week (start) → 0.6–2.4 mg/week
Effects & Properties
Water Retention No
Aromatization No
Hepatotoxicity No
Hair Loss Risk (HBR) Low (indirect)
Acne No
What Is Dragon Pharma Cagrilintide 10mg?
Dragon Pharma Cagrilintide 10mg is a pharmaceutical-grade, long-acting amylin analog peptide engineered to mimic the natural hormone amylin — co-secreted alongside insulin by the pancreas to regulate appetite, satiety, and blood sugar levels. Unlike natural amylin, which breaks down rapidly in the body, Dragon Pharma Cagrilintide has been structurally modified for exceptional stability, enabling once-weekly subcutaneous dosing rather than multiple daily injections.
Originally developed as a next-generation metabolic peptide for obesity management, Cagrilintide targets the biological root causes of overeating — acting directly on amylin and calcitonin receptors in the hypothalamus to suppress hunger, extend post-meal fullness, and reduce overall caloric intake. It represents a fundamentally different mechanism from GLP-1 receptor agonists like Semaglutide, making it one of the most compelling dual-pathway stack candidates in metabolic peptide research today.
How Does Dragon Pharma Cagrilintide 10mg Work?
Cagrilintide's mechanism operates through the amylin/calcitonin receptor pathway — entirely separate from the incretin-based pathway targeted by GLP-1 agonists. This distinction is what makes it uniquely valuable both as a standalone research compound and as a combination therapy.
- Slows gastric emptying — delays food transit from the stomach, extending the duration of post-meal satiety and reducing the urge to snack between meals
- Activates hypothalamic satiety centers — binds to amylin and calcitonin receptors in the brain regions governing hunger and appetite regulation, directly reducing food intake signals
- Improves glycemic control — by slowing digestion, Cagrilintide blunts sharp post-meal blood sugar spikes, supporting energy balance and reducing insulin demand
- Sustained appetite suppression — engineered structural modifications give Cagrilintide a long half-life, maintaining steady receptor activity throughout the week with a single injection
- Synergistic with GLP-1 therapies — because it operates on a completely separate receptor pathway from semaglutide or liraglutide, combining the two creates a dual-mechanism satiety effect that outperforms either compound alone in clinical research
Dragon Pharma Cagrilintide 10mg – Key Benefits
- Significant body weight reduction — clinical data shows meaningful reductions in body weight versus placebo, particularly at mid-to-higher dose ranges
- Sustained fullness and reduced caloric intake — works with the body's own hormonal signaling rather than suppressing appetite through stimulant mechanisms
- Improved glycemic control — smooths post-meal glucose fluctuations, supporting metabolic health and reducing cardiometabolic risk factors over time
- Once-weekly convenience — superior adherence profile compared to legacy amylin analogs like pramlintide, which required multiple daily injections around meals
- Non-stimulant mechanism — no catecholamine elevation, no cardiovascular stimulant load, no tolerance buildup associated with compounds like phentermine
- Powerful stack synergy — combining Cagrilintide with GLP-1 agonists delivers greater weight loss than either therapy alone, making it the leading dual-pathway option in obesity peptide research
Dragon Pharma Cagrilintide 10mg Dosage Guide
Cagrilintide is administered via subcutaneous injection, typically into the abdomen or thigh, on a once-weekly schedule. The following dosage ranges reflect data from clinical research and are provided strictly for informational purposes.
| Protocol |
Weekly Dose |
Notes |
| Starting / Titration |
0.3 – 0.6 mg/week |
Minimize GI side effects |
| Maintenance |
1.2 – 2.4 mg/week |
Consistent appetite suppression |
| Advanced / Combination |
2.4 – 4.5 mg/week |
Maximum weight-loss signal in trials |
Titration is strongly recommended. Beginning at a lower dose and gradually escalating over several weeks allows the body to adapt to slowed gastric emptying and reduces the intensity of early GI side effects such as nausea and abdominal discomfort.
Cagrilintide is designed for ongoing use rather than short cycles — appetite suppression effects accumulate over weeks, with the most significant weight-loss outcomes observed in sustained-use research protocols.
Stacking Dragon Pharma Cagrilintide 10mg
Cagrilintide's greatest research potential lies in combination protocols. Because it acts on the amylin/calcitonin receptor pathway — entirely independent of incretin signaling — it adds a separate satiety axis on top of GLP-1 or GLP-1/GIP therapies without receptor overlap or redundancy.
Evidence-supported combinations:
- Cagrilintide + Semaglutide: The most clinically studied combination. GLP-1 receptor activation via semaglutide combined with amylin pathway activation via Cagrilintide produces greater weight reduction than either compound alone — the dual-mechanism advantage in practice. Ideal for researchers studying maximal appetite suppression and glycemic control.
- Cagrilintide + Reta Peptide: Reta-Peptide's triple agonist activity (GLP-1/GIP/Glucagon) combined with Cagrilintide's amylin pathway creates a broad-spectrum metabolic stack targeting multiple hunger and energy-regulation axes simultaneously.
- Cagrilintide + AOD-9604: AOD-9604 (GH Fragment 176–191) drives lipolysis — the direct breakdown of stored fat for energy. Cagrilintide contributes sustained appetite suppression and caloric intake reduction. Together they address both sides of the energy equation: reduced input and increased fat mobilization.
Combination considerations: When stacking Cagrilintide with insulin-stimulating compounds, monitor closely for hypoglycemia risk. GI side effects may be amplified during the titration phase of combination protocols — gradual dose escalation on both compounds is advised.
Side Effects of Cagrilintide
Dragon Pharma Cagrilintide 10mg carries a side effect profile consistent with its amylin analog mechanism — predominantly gastrointestinal and dose-dependent. Clinical research indicates good overall tolerability, particularly when titration protocols are followed.
- Nausea and vomiting — most commonly reported, especially during initial dose escalation; typically resolves as the body adapts to slowed gastric emptying
- Constipation and abdominal discomfort — a direct consequence of delayed gastric transit; managed with adequate hydration and dietary fiber
- Reduced appetite to discomfort — some users experience satiety signals stronger than intended, particularly at higher doses; resolved by dose reduction
- Injection site reactions — mild redness, itching, or irritation at the subcutaneous injection site; rotate injection locations to minimize
- Headache or dizziness — likely linked to shifts in energy intake and appetite regulation during the adaptation phase
- Gallbladder considerations — as with GLP-1 therapies, rapid weight loss may increase gallstone risk in susceptible individuals
- Hypoglycemia risk — rare when used alone; elevated when combined with insulin or insulin-stimulating compounds; monitor blood glucose in combination protocols
Long-term safety data is still being established through ongoing Phase III trials. Dragon Pharma Cagrilintide 10mg is intended for research purposes and should be used under appropriate supervision.
Why Dragon Pharma Cagrilintide 10mg?
Dragon Pharma is a globally recognized pharmaceutical-grade manufacturer trusted by researchers worldwide for consistent compound purity, accurate dosing, and rigorous third-party quality verification. Dragon Pharma Cagrilintide 10mg delivers:
- Verified peptide concentration — accurate 10mg per vial, confirmed by independent lab testing
- Pharmaceutical-grade synthesis ensuring structural integrity, stability, and consistent receptor activity
- Trusted manufacturing standards with documented third-party lab verification
As a long-acting amylin analog targeting hypothalamic satiety centers and glycemic control, Dragon Pharma Cagrilintide 10mg stands apart from incretin-based peptides through its unique dual-pathway research potential. Third-party lab tested and pharmaceutical-grade, it is the definitive choice for serious metabolic peptide research.
